PO65 | Utilization of emicizumab in acquired hemophilia A: a case report
Background: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation Factor VIII (FVIII). Treatment consists of bleeding control with bypassing agents and immunosuppressive therapy (IST). Emicizumab, a bispecific antibody that mimics the function of act...
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
PAGEPress Publications
2025-08-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|